ATE449099T1 - Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren - Google Patents
Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitorenInfo
- Publication number
- ATE449099T1 ATE449099T1 AT03785075T AT03785075T ATE449099T1 AT E449099 T1 ATE449099 T1 AT E449099T1 AT 03785075 T AT03785075 T AT 03785075T AT 03785075 T AT03785075 T AT 03785075T AT E449099 T1 ATE449099 T1 AT E449099T1
- Authority
- AT
- Austria
- Prior art keywords
- trifluormethyl
- aminopurine
- phosphodiesterase
- inhibitors
- derivatives
- Prior art date
Links
- JPFOYYRMIMSYQZ-UHFFFAOYSA-N 2-(trifluoromethyl)-7h-purin-6-amine Chemical class NC1=NC(C(F)(F)F)=NC2=C1NC=N2 JPFOYYRMIMSYQZ-UHFFFAOYSA-N 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/14—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with two methyl radicals in positions 1 and 3 and two methyl radicals in positions 7, 8, or 9
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40176502P | 2002-08-08 | 2002-08-08 | |
| PCT/US2003/024914 WO2004014913A2 (en) | 2002-08-08 | 2003-08-08 | Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE449099T1 true ATE449099T1 (de) | 2009-12-15 |
Family
ID=31715731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03785075T ATE449099T1 (de) | 2002-08-08 | 2003-08-08 | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7332486B2 (de) |
| EP (1) | EP1529049B1 (de) |
| JP (1) | JP2005538134A (de) |
| CN (1) | CN1688580A (de) |
| AT (1) | ATE449099T1 (de) |
| AU (1) | AU2003264017B2 (de) |
| CA (1) | CA2494028A1 (de) |
| DE (1) | DE60330150D1 (de) |
| WO (1) | WO2004014913A2 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1383767A1 (de) * | 2001-02-08 | 2004-01-28 | Memory Pharmaceutical Corporation | Trifluormethylpurine als phosphodiesterase-4-hemmer |
| US7332486B2 (en) * | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| JP2005538133A (ja) * | 2002-08-08 | 2005-12-15 | メモリー・ファーマシューティカルズ・コーポレイション | ホスホジエステラーゼ４阻害剤 |
| NZ546611A (en) | 2003-09-18 | 2010-02-26 | Conforma Therapeutics Corp | Novel heterocyclic compounds as HSP90-inhibitors |
| BRPI0609509A2 (pt) | 2005-03-30 | 2010-04-13 | Conforma Therapeutics Corp | composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável |
| WO2006123639A1 (ja) * | 2005-05-18 | 2006-11-23 | Asahi Kasei Pharma Corporation | ピリミジン誘導体 |
| BRPI0708337A2 (pt) | 2006-02-28 | 2011-05-24 | Helicon Therapeutics Inc | pipirazinas terapêutica como inibidores pde4 |
| FR2898057B1 (fr) * | 2006-03-06 | 2008-07-04 | Centre Nat Rech Scient | Utilisation de composes derives de l'adenine pour le traitement de lupus |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| SG172391A1 (en) | 2009-01-19 | 2011-07-28 | Abbott Lab | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| NZ593594A (en) * | 2009-01-19 | 2013-08-30 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP2308866A1 (de) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| BR112012018358A2 (pt) | 2009-12-21 | 2016-08-09 | Bayer Cropscience Ag | tienilpiri(mi)dinilazol e seu uso para controlar fungos fitopatogênicos |
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| US9493464B2 (en) | 2012-02-29 | 2016-11-15 | The Scripps Research Institute | Wee1 degradation inhibitors |
| BR112014029161A2 (pt) * | 2012-05-22 | 2017-06-27 | Genentech Inc | benzamidas n-substituídas e seu uso no tratamento de dor |
| BR112015000187A2 (pt) | 2012-07-06 | 2017-06-27 | Genentech Inc | benzamidas substituídas com n e métodos de uso das mesmas |
| BR112015022488A2 (pt) | 2013-03-14 | 2017-07-18 | Genentech Inc | triazolopiridinas substituídas e métodos de uso das mesmas |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
| EP3166939B1 (de) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutische verbindungen und verfahren zur verwendung davon |
| KR102412146B1 (ko) | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
| WO2016191312A1 (en) | 2015-05-22 | 2016-12-01 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| PE20181003A1 (es) | 2015-09-28 | 2018-06-26 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso |
| CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| CA3013698A1 (en) | 2016-02-09 | 2017-08-17 | Establishment Labs S.A. | Transponders and sensors for implantable medical devices and methods of use thereof |
| EP3854782A1 (de) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituierte benzamide und verfahren zur verwendung davon |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| SG11201903348UA (en) | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| WO2018175707A1 (en) | 2017-03-24 | 2018-09-27 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| CN108395432A (zh) * | 2018-01-15 | 2018-08-14 | 吴江信凯医药科技有限公司 | 一种2-三氟甲基-6-氨基嘌呤的制备方法 |
| EP3759098A1 (de) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridinsulfonamidverbindungen und deren verwendung gegen schmerz und verwandte störungen |
| EP3774801A1 (de) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Hydro-pyrido-verbindungen mit kondensierten ringen als natriumkanalinhibitoren |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2021026803A1 (en) | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3919192A (en) | 1972-05-22 | 1975-11-11 | Icn Pharmaceuticals | 5-Amino-4-substituted imidazole nucleotides |
| US3917583A (en) | 1972-08-04 | 1975-11-04 | Icn Pharmaceuticals | 2-Substituted cyclic AMP derivatives |
| AR205247A1 (es) | 1973-02-07 | 1976-04-21 | Icn Pharmaceuticals | Procedimiento para preparar derivados de amp 2-substituidos |
| GB8817651D0 (en) | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
| US5013829A (en) | 1989-04-26 | 1991-05-07 | University Of Iowa Research Foundation | Stable congener of 2',3'-dideoxyadenosine |
| US5935978A (en) | 1991-01-28 | 1999-08-10 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
| ATE150447T1 (de) | 1992-06-15 | 1997-04-15 | Celltech Therapeutics Ltd | Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren |
| DE4230755A1 (de) | 1992-09-14 | 1994-03-17 | Schering Ag | Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen |
| US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| TW263495B (de) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| US5525606A (en) | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
| US5864037A (en) | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
| US5744473A (en) | 1996-09-16 | 1998-04-28 | Euro-Celtique, S.A. | PDE IV inhibitors: "bis-compounds" |
| DE19702785A1 (de) | 1997-01-27 | 1998-07-30 | Bayer Ag | Neue cyclische Harnstoffderivate |
| CA2295106C (en) | 1997-06-24 | 2007-03-13 | Nikken Chemicals Co., Ltd. | 3-anilino-2-cycloalkenone derivatives |
| CA2309350C (en) | 1997-11-12 | 2007-04-03 | Mitsubishi Chemical Corporation | Purine derivatives and medicaments comprising the same as active ingredient |
| US6040447A (en) | 1997-12-12 | 2000-03-21 | Euro-Celtique S.A. | Purine compounds having PDE IV inhibitory activity and methods of synthesis |
| JP3542482B2 (ja) | 1997-12-25 | 2004-07-14 | 日研化学株式会社 | ３−アニリノ−２−シクロアルケノン誘導体 |
| US6319928B1 (en) | 1998-11-30 | 2001-11-20 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
| DE19935209A1 (de) | 1999-07-27 | 2001-02-08 | Truss Michael C | Verwendung von Substanzen, die den intrazellulären Gehalt von zyklischem Adenosinmonophosphat (cAMP) erhöhen oder die Aktivität cAMP-bindender Proteine stimulieren, zur Behandlung von Erkrankungen der Harnblase |
| GB0011802D0 (en) | 2000-05-16 | 2000-07-05 | Smithkline Beecham | Method for enhancing cognitive function |
| EP1383767A1 (de) * | 2001-02-08 | 2004-01-28 | Memory Pharmaceutical Corporation | Trifluormethylpurine als phosphodiesterase-4-hemmer |
| US7332486B2 (en) * | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| JP2005538133A (ja) | 2002-08-08 | 2005-12-15 | メモリー・ファーマシューティカルズ・コーポレイション | ホスホジエステラーゼ４阻害剤 |
-
2003
- 2003-08-08 US US10/636,979 patent/US7332486B2/en not_active Expired - Fee Related
- 2003-08-08 CN CNA038239779A patent/CN1688580A/zh active Pending
- 2003-08-08 EP EP03785075A patent/EP1529049B1/de not_active Expired - Lifetime
- 2003-08-08 WO PCT/US2003/024914 patent/WO2004014913A2/en not_active Ceased
- 2003-08-08 DE DE60330150T patent/DE60330150D1/de not_active Expired - Lifetime
- 2003-08-08 AU AU2003264017A patent/AU2003264017B2/en not_active Expired - Fee Related
- 2003-08-08 AT AT03785075T patent/ATE449099T1/de not_active IP Right Cessation
- 2003-08-08 CA CA002494028A patent/CA2494028A1/en not_active Abandoned
- 2003-08-08 JP JP2004527913A patent/JP2005538134A/ja active Pending
-
2008
- 2008-02-05 US US12/026,198 patent/US20080139583A1/en not_active Abandoned
-
2009
- 2009-02-26 US US12/393,634 patent/US20100004236A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20070093510A1 (en) | 2007-04-26 |
| CA2494028A1 (en) | 2004-02-19 |
| DE60330150D1 (en) | 2009-12-31 |
| US7332486B2 (en) | 2008-02-19 |
| CN1688580A (zh) | 2005-10-26 |
| WO2004014913A3 (en) | 2004-07-29 |
| WO2004014913A2 (en) | 2004-02-19 |
| AU2003264017B2 (en) | 2010-05-27 |
| AU2003264017A1 (en) | 2004-02-25 |
| US20080139583A1 (en) | 2008-06-12 |
| JP2005538134A (ja) | 2005-12-15 |
| EP1529049B1 (de) | 2009-11-18 |
| EP1529049A2 (de) | 2005-05-11 |
| US20100004236A1 (en) | 2010-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60330150D1 (en) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
| TW200602322A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
| ATE506354T1 (de) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
| NO20062950L (no) | 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet | |
| DE60313472D1 (de) | Pyrrolidindion-substituierte piperidin-phthalazone als pde4-inhibitoren | |
| ATE491703T1 (de) | Phthalazinonderivate | |
| DE60309848D1 (de) | Purinderivate als kinaseinhibitoren | |
| BR0213981A (pt) | Fotoiniciadores difuncionais | |
| SE0000540D0 (sv) | New compounds | |
| YU57603A (sh) | Inhibitori fosfodiesteraze 4 | |
| CY1106132T1 (el) | Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου | |
| DE60233884D1 (de) | 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen | |
| BR0207302A (pt) | Trifluorometilpurinas como inibidores da fosfodiesterase 4 | |
| DE60112306D1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
| SE0103710D0 (sv) | Compounds | |
| ATE399168T1 (de) | Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren | |
| IL166164A0 (en) | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors | |
| DE60041001D1 (de) | Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien | |
| ATE445619T1 (de) | Pyridinylpyrazolopyrimidinon-derivate als pde 7 inhibitoren | |
| BRPI0416678A (pt) | pirazolpirimidinas | |
| ATE374189T1 (de) | Phthalazinon-derivate als pde 4 hemmer | |
| EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
| DE60110124D1 (de) | Kondensierte pyrazindionderivate als pde inhibitoren | |
| GB0215392D0 (en) | Chemical compounds | |
| EA200600608A1 (ru) | Производные имидазопиридина как ингибиторы индуцируемой no-синтазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1529049 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |